Delivery Order SPE2DR25D1053-SPE2DR26FT396
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,344.41 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pens on September 10, 2025, with completion expected by September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a branded pharmaceutical product used in diabetes management,...
- The Defense Logistics Agency awarded a $26,741.23 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through...
- The Defense Logistics Agency (DLA) awarded a $2,750.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pens on September 11, 2025, with completion scheduled for September 12, 2025. This non-set-aside award was made competitively and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The pharmaceutical distributor, headquartered...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,822.64 to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a prescription medication...
- The Defense Logistics Agency awarded a $2,776.41 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on September 22, 2025, with completion targeted for September 23, 2025. This is a firm fixed price, non-set-aside contract with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $4,515.92 to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This non-competitive delivery order represents a firm fixed-price pharmaceutical supply transaction to be performed at the vendor's Conshohocken, Pennsylvania location. Mounjaro is a diabetes medication, consistent with AmerisourceBergen's extensive portfolio of pharmaceutical products...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,456.89 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 mL pens. This firm fixed-price, competitively awarded delivery order was issued on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's competitive standing...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,323.06 on August 13, 2025, for the supply of Mounjaro 15 mg/0.5 mL pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 14, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and primary distribution operations. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,767.20 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 ml pens (0.5 ml) with an ultimate completion date of September 30, 2025. This firm fixed-price delivery order, awarded on September 29, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this contract at its corporate...
- The Defense Logistics Agency awarded a $3,381.47 delivery order to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pens on June 20, 2025, with completion expected by June 23, 2025. This firm fixed-price contract represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, aligning with AmerisourceBergen's extensive portfolio of pharmaceutical products supplied...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT396Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,927.16 to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens (0.5 mL) on October 28, 2025, with an ultimate completion date of October 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a pharmaceutical product used for diabetes management, consistent with AmerisourceBergen's extensive portfolio of pharmaceutical supplies supporting federal medical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.999 billion through December 2026. As a prime vendor for federal medical supply needs, AmerisourceBergen supplies critical pharmaceutical products and medical commodities to support military healthcare systems and other federal government agencies. The company's federal contract portfolio demonstrates its capability to meet procurement requirements through open competition across a wide range of therapeutic domains, including specialty medications, vaccines, and medical supplies serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.9k | 10/28/25 |